You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 30, 2024

CLINICAL TRIALS PROFILE FOR NEOPROFEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NEOPROFEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00833365 ↗ Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Terminated H. Lundbeck A/S N/A 2009-01-01 The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late use is defined as medication given when infant is more than 96 hrs old.
NCT00833365 ↗ Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Terminated University of Utah N/A 2009-01-01 The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late use is defined as medication given when infant is more than 96 hrs old.
NCT00961753 ↗ Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Terminated OSF Healthcare System Phase 4 2009-08-01 The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NEOPROFEN

Condition Name

Condition Name for NEOPROFEN
Intervention Trials
Patent Ductus Arteriosus 2
Biliary Colic 1
Prematurity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NEOPROFEN
Intervention Trials
Ductus Arteriosus, Patent 2
Retinopathy of Prematurity 1
Colic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NEOPROFEN

Trials by Country

Trials by Country for NEOPROFEN
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NEOPROFEN
Location Trials
New York 1
Arizona 1
Illinois 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NEOPROFEN

Clinical Trial Phase

Clinical Trial Phase for NEOPROFEN
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NEOPROFEN
Clinical Trial Phase Trials
Terminated 2
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NEOPROFEN

Sponsor Name

Sponsor Name for NEOPROFEN
Sponsor Trials
Food and Drug Administration (FDA) 1
State University of New York - Downstate Medical Center 1
H. Lundbeck A/S 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NEOPROFEN
Sponsor Trials
Other 5
U.S. Fed 1
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.